CFA
PCRX icon

Cahill Financial Advisors’s Pacira BioSciences PCRX Stock Holding History

Cahill Financial Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-66
Closed -$4K – 597
2021
Q3 		$4K Buy
+66
New +$3.8K ﹤0.01% 725

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Cahill Financial Advisors's PCRX Position: Q4 2021 in Review

Cahill Financial Advisors sold out of Pacira BioSciences (PCRX) in Q4 2021, closing a stake of 66 shares — an estimated $4K sold.

Cahill Financial Advisors first reported a position in PCRX in Q3 2021 and held it in 1 quarter. The position peaked at $4K in Q3 2021. 276 funds tracked by Wall St. Rank hold PCRX as of Q4 2021.

  • Cahill Financial Advisors reported no remaining Pacira BioSciences position as of Q4 2021 after selling out during the quarter.
  • Cahill Financial Advisors sold 66 Pacira BioSciences shares in Q4 2021, an estimated $4K.
  • Cahill Financial Advisors first reported a position in Pacira BioSciences in Q3 2021 and held it in 1 quarter.
  • Cahill Financial Advisors's Pacira BioSciences position peaked at $4K in Q3 2021.
  • 276 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.